Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study.

Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, von Haehling S, Adler SH, Zhao J, Singh B, Lavin PT, McCullough PA, Kosiborod M, Packham DK; ZS-005 Study Investigators.

Clin J Am Soc Nephrol. 2019 May 20. pii: CJN.12651018. doi: 10.2215/CJN.12651018. [Epub ahead of print]

PMID:
31110051
2.

One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study).

Wong G, Hope RL, Howard K, Chapman JR, Castells A, Roger SD, Bourke MJ, Macaskill P, Turner R, Williams G, Lim WH, Lok CE, Diekmann F, Cross NB, Sen S, Allen RDM, Chadban SJ, Pollock CA, Tong A, Teixeira-Pinto A, Yang JYH, Williams N, Au EHK, Kieu A, James L, Craig JC.

J Am Soc Nephrol. 2019 Apr 30. pii: ASN.2018121232. doi: 10.1681/ASN.2018121232. [Epub ahead of print]

PMID:
31040191
3.

Nail clubbing in laxative abuse: case report and review of the literature.

Charlton OA, Dickison P, Smith SD, Roger SD.

J Eat Disord. 2019 Mar 5;7:6. doi: 10.1186/s40337-019-0236-4. eCollection 2019.

4.

Beware what lies beneath: a case of a gigantic cutaneous squamous cell carcinoma.

Dickison P, Roger SD, Howard V, Smith SD.

Clin Exp Dermatol. 2019 Jun;44(4):465-466. doi: 10.1111/ced.13791. Epub 2018 Sep 26. No abstract available.

PMID:
30259551
5.

Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).

Wong ATY, Mannix C, Grantham JJ, Allman-Farinelli M, Badve SV, Boudville N, Byth K, Chan J, Coulshed S, Edwards ME, Erickson BJ, Fernando M, Foster S, Haloob I, Harris DCH, Hawley CM, Hill J, Howard K, Howell M, Jiang SH, Johnson DW, Kline TL, Kumar K, Lee VW, Lonergan M, Mai J, McCloud P, Peduto A, Rangan A, Roger SD, Sud K, Torres V, Vliayuri E, Rangan GK.

BMJ Open. 2018 Jan 21;8(1):e018794. doi: 10.1136/bmjopen-2017-018794. Erratum in: BMJ Open. 2018 Aug 5;8(8):e018794corr1.

6.

Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease.

Roger SD.

Clin Kidney J. 2017 Dec;10(Suppl 1):i9-i15. doi: 10.1093/ckj/sfx100. Epub 2017 Nov 28. Review.

7.

Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Wyck DV, Meier Y, Larroque S, Perrin A, Roger SD.

Clin Nephrol. 2017 Dec;88(12):301-310. doi: 10.5414/CN109198.

8.

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.

Roger SD, Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Cronin M, Meier Y, Larroque S, Macdougall IC; FIND-CKD Study Investigators.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1530-1539. doi: 10.1093/ndt/gfw264.

9.

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Roger SD; FIND-CKD Study investigators.

BMC Nephrol. 2017 Jan 17;18(1):24. doi: 10.1186/s12882-017-0444-6.

10.

Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis.

Roger SD, Tio M, Park HC, Choong HL, Goh B, Cushway TR, Stevens V, Macdougall IC.

Nephrology (Carlton). 2017 Dec;22(12):969-976. doi: 10.1111/nep.12940. Review.

11.

Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.

Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC.

PLoS One. 2016 Jun 8;11(6):e0157063. doi: 10.1371/journal.pone.0157063. eCollection 2016.

12.

Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?

Sindone A, Erlich J, Lee C, Newman H, Suranyi M, Roger SD.

Intern Med J. 2016 Mar;46(3):364-72. doi: 10.1111/imj.12975. Review.

PMID:
26968600
13.

A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.

Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S; PHI112844 Investigators.

Am J Kidney Dis. 2016 Jun;67(6):861-71. doi: 10.1053/j.ajkd.2015.11.021. Epub 2016 Jan 27.

14.

New data on the safety of IV iron-but why the discrepancy with FIND-CKD?

Macdougall IC, Roger SD.

Kidney Int. 2015 Dec;88(6):1445-1446. doi: 10.1038/ki.2015.302. No abstract available.

PMID:
26649664
15.

Sodium zirconium cyclosilicate in hyperkalemia.

Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B.

N Engl J Med. 2015 Jan 15;372(3):222-31. doi: 10.1056/NEJMoa1411487. Epub 2014 Nov 21.

16.

Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B.

JAMA. 2014 Dec 3;312(21):2223-33. doi: 10.1001/jama.2014.15688. Erratum in: JAMA. 2015 Feb 3;313(5):526. Dosage error in text.

PMID:
25402495
17.

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators.

Nephrol Dial Transplant. 2014 Nov;29(11):2075-84. doi: 10.1093/ndt/gfu201. Epub 2014 Jun 2.

18.

Peginesatide to Manage Anemia in Chronic Kidney Disease Patients on Peritoneal Dialysis.

Zabaneh R, Roger SD, El-Shahawy M, Roppolo M, Runyan G, O'Neil J, Qiu P.

Perit Dial Int. 2015 Jul-Aug;35(4):481-9. doi: 10.3747/pdi.2012.00224. Epub 2014 Mar 1.

19.

Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis.

Roger SD, Kolmakova E, Fung M, Malecki R, Vinhas J, Dellanna F, Thomas M, Manamley N, Ferenczi S.

Nephrology (Carlton). 2014 May;19(5):266-74. doi: 10.1111/nep.12214.

PMID:
24506498
20.

The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale.

Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD; FIND-CKD Study Investigators.

Nephrol Dial Transplant. 2014 Apr;29(4):843-50. doi: 10.1093/ndt/gft424. Epub 2013 Oct 29.

21.

ACEIs for cardiovascular risk reduction--have we taken our eye off the ball?

Sindone A, Erlich J, Perkovic V, Suranyi M, Newman H, Lee C, Barin E, Roger SD.

Aust Fam Physician. 2013 Sep;42(9):634-8.

22.

A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE.

Roger SD, Jassal SV, Woodward MC, Soroka S, McMahon LP.

Int Urol Nephrol. 2014 Feb;46(2):469-75. doi: 10.1007/s11255-013-0512-1. Epub 2013 Aug 28.

PMID:
23982766
23.

Test performance characteristics of quantitative nucleic acid testing for polyomaviruses in kidney and kidney-pancreas transplant recipients.

Myint TM, Turner RM, Craig JC, Cross NB, Kable K, Nankivell BJ, Chapman JR, Webster AC, O'Connell P, Dwyer DE, Jeoffreys N, Roger SD, Wong G.

Clin Transplant. 2013 Sep-Oct;27(5):E571-9. doi: 10.1111/ctr.12195. Epub 2013 Aug 17.

PMID:
23952788
24.

Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa.

Fishbane S, Roger SD, Martin E, Runyan G, O'Neil J, Qiu P, Locatelli F.

Clin J Am Soc Nephrol. 2013 Apr;8(4):538-45. doi: 10.2215/CJN.03440412. Epub 2012 Dec 14.

25.

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights.

Macdougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C.

Kidney Int. 2012 Apr;81(8):727-32. doi: 10.1038/ki.2011.500. Epub 2012 Feb 15. Review.

26.
27.

Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol.

Wong G, Howard K, Chapman JR, Tong A, Bourke MJ, Hayen A, Macaskill P, Hope RL, Williams N, Kieu A, Allen R, Chadban S, Pollock C, Webster A, Roger SD, Craig JC.

BMC Public Health. 2011 Jun 29;11:516. doi: 10.1186/1471-2458-11-516.

28.

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, Golper TA, Ruangkanchanasetr P, Lee HY, Wu KD, Nowicki M, Ladanyi A, Martínez-Castelao A, Beyer U, Dougherty FC.

Nephrol Dial Transplant. 2011 Dec;26(12):3980-6. doi: 10.1093/ndt/gfr160. Epub 2011 Apr 19.

29.

Hypercalcaemia as a prodromal feature of indolent Pneumocystis jivorecii after renal transplantation.

Bency R, Roger SD, Elder GJ.

Nephrol Dial Transplant. 2011 May;26(5):1740-2. doi: 10.1093/ndt/gfr051. Epub 2011 Mar 4.

PMID:
21378150
30.

Diagnosis and management of iron deficiency anaemia: a clinical update.

Pasricha SR, Flecknoe-Brown SC, Allen KJ, Gibson PR, McMahon LP, Olynyk JK, Roger SD, Savoia HF, Tampi R, Thomson AR, Wood EM, Robinson KL.

Med J Aust. 2010 Nov 1;193(9):525-32. Review.

PMID:
21034387
31.

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD.

Nephrol Dial Transplant. 2011 May;26(5):1599-607. doi: 10.1093/ndt/gfq613. Epub 2010 Oct 7.

32.

Biosimilars: current status and future directions.

Roger SD.

Expert Opin Biol Ther. 2010 Jul;10(7):1011-8. doi: 10.1517/14712591003796553. Review.

PMID:
20384525
33.

Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.

McMahon LP, Kent AB, Kerr PG, Healy H, Irish AB, Cooper B, Kark A, Roger SD.

Nephrol Dial Transplant. 2010 Mar;25(3):920-6. doi: 10.1093/ndt/gfp584. Epub 2009 Nov 10.

PMID:
19906658
34.

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.

Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA.

Am J Kidney Dis. 2009 Feb;53(2):197-207. doi: 10.1053/j.ajkd.2008.09.021. Epub 2008 Dec 24.

PMID:
19110359
35.

Biosimilars: it's not as simple as cost alone.

Roger SD, Goldsmith D.

J Clin Pharm Ther. 2008 Oct;33(5):459-64. doi: 10.1111/j.1365-2710.2008.00942.x.

PMID:
18834359
36.

Extended administration of erythropoiesis-stimulating agents for optimising the management of renal anaemia: what is the evidence?

Roger SD.

Int J Clin Pract. 2008 Sep;62(9):1413-22. doi: 10.1111/j.1742-1241.2008.01846.x. Review.

PMID:
18793377
37.

Longitudinal analysis of performance of estimated glomerular filtration rate as renal function declines in chronic kidney disease.

Lee D, Levin A, Roger SD, McMahon LP.

Nephrol Dial Transplant. 2009 Jan;24(1):109-16. doi: 10.1093/ndt/gfn477. Epub 2008 Aug 28.

PMID:
18755849
38.

A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.

Roger SD, Suranyi MG, Walker RG, Disney A, Isbel NM, Kairaitis L, Pollock CA, Brown FG, Chow J, Truman MI, Ulyate KA; COMFORT study group.

Curr Med Res Opin. 2008 Aug;24(8):2181-7. doi: 10.1185/03007990802240552. Epub 2008 Jun 18.

PMID:
18565240
39.

Biosimilars: opportunity or cause for concern?

Roger SD, Mikhail A.

J Pharm Pharm Sci. 2007;10(3):405-10. Review.

40.

Research degrees for medical graduates.

Roger SD.

Intern Med J. 2007 Jul;37(7):511. No abstract available.

PMID:
17547739
41.

Understanding epoetin use: databases or clinical trials?

Roger SD.

Nephrology (Carlton). 2007 Apr;12(2):118-9. No abstract available.

PMID:
17371331
42.

Chronic kidney disease, anemia, and epoetin.

Roger SD.

N Engl J Med. 2007 Mar 1;356(9):958; author reply 958-9. No abstract available.

PMID:
17338047
43.

Epoetin trials: randomised controlled trials don't always mimic observational data.

Roger SD, Levin A.

Nephrol Dial Transplant. 2007 Mar;22(3):684-6. Epub 2007 Jan 8. No abstract available.

PMID:
17210590
44.

Proton pump inhibitors: indigestion for nephrologists!

Roger SD.

Nephrology (Carlton). 2006 Oct;11(5):379-80. No abstract available.

PMID:
17014548
45.

Implementing iron management clinical practice guidelines in patients with chronic kidney disease having dialysis.

Irving MJ, Craig JC, Gallagher M, McDonald S, Polkinghorne KR, Walker RG, Roger SD.

Med J Aust. 2006 Sep 18;185(6):310-4.

PMID:
16999671
46.

Biosimilars: how similar or dissimilar are they?

Roger SD.

Nephrology (Carlton). 2006 Aug;11(4):341-6. Review.

PMID:
16889575
47.

Effect of early correction of anemia on the progression of CKD.

Rossert J, Levin A, Roger SD, Hörl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM.

Am J Kidney Dis. 2006 May;47(5):738-50.

PMID:
16632012
48.

Proton pump inhibitors and acute interstitial nephritis.

Geevasinga N, Coleman PL, Webster AC, Roger SD.

Clin Gastroenterol Hepatol. 2006 May;4(5):597-604.

PMID:
16630752
49.

Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients.

Hibberd AD, Trevillian PR, Roger SD, Wlodarczyk JH, Stein AM, Bohringer EG, Milson-Hawke SM.

Transplantation. 2006 Mar 15;81(5):711-7.

PMID:
16534473
50.

Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.

O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA; CHARM Committees and Investigators.

Circulation. 2006 Feb 21;113(7):986-94. Epub 2006 Feb 13.

PMID:
16476847

Supplemental Content

Loading ...
Support Center